FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
Go back to FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 29.73 +0.15 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.58 | 52 Week High | $42.49 | |||
| Open | $29.26 | 52 Week Low | $16.64 | |||
| Day High | $29.83 | P/E | N/A | |||
| Day Low | $29.15 | EPS | $-0.42 | |||
| Volume | 879,346 | |||||
